← Back to Search

Anti-mitotic Agent

NanoPac for Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by NanOlogy, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, weeks 1, 2, 4, 5, 6, 8, 9, 10, 12, 18, and 24
Awards & highlights

Study Summary

This trial is testing if NanoPac, a kind of chemotherapy, can help treat lung cancer by being injected directly into the tumor.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, weeks 1, 2, 4, 5, 6, 8, 9, 10, 12, 18, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, weeks 1, 2, 4, 5, 6, 8, 9, 10, 12, 18, and 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with treatment emergent adverse events
Secondary outcome measures
Change in tumor dimensions
Concentration of paclitaxel in the systemic circulation post-injection
Overall survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NanoPacExperimental Treatment1 Intervention
Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
2021
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

NanOlogy, LLCLead Sponsor
10 Previous Clinical Trials
160 Total Patients Enrolled
US Biotest, Inc.Industry Sponsor
17 Previous Clinical Trials
350 Total Patients Enrolled
Shelagh Verco, PhDStudy DirectorUS Biotest, Inc.
3 Previous Clinical Trials
71 Total Patients Enrolled

Media Library

NanoPac (Anti-mitotic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04314895 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: NanoPac
Non-Small Cell Lung Cancer Clinical Trial 2023: NanoPac Highlights & Side Effects. Trial Name: NCT04314895 — Phase 2
NanoPac (Anti-mitotic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04314895 — Phase 2
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top